Global Intravenous (IV) Ibuprofen Market to Reach US$ 12.6 Billion by 2032, Driven by Rising Number of Surgical Procedures

August 25, 2023 | Healthcare

According to the latest report by IMARC Group, titled “Intravenous (IV) Ibuprofen Market Report by Product Dose (100 Mg Dose, 200 Mg Dose, 400 Mg Dose, 800 Mg Dose), Indication (Pain/Inflammatory, Fever), Age Group (Pediatrics, Adults), and Region 2024-2032,” the global intravenous (IV) ibuprofen market size reached US$ 6.8 Billion in 2023. Intravenous (IV) ibuprofen is a pharmaceutical formulation of the well-known nonsteroidal anti-inflammatory drug (NSAID) Ibuprofen, administered intravenously rather than orally. It is primarily used for the management of pain and reduction of inflammation in patients unable to take oral medications due to various medical conditions or surgical procedures. The IV Ibuprofen is typically indicated for short-term treatment and is not intended for chronic use. The intravenous route of administration allows for rapid absorption of the drug into the bloodstream, leading to faster onset of action compared to oral Ibuprofen. This makes it particularly useful in post-operative settings, where timely pain relief is crucial for patient comfort and recovery. As with any medication, IV Ibuprofen carries potential side effects and should be used under the supervision of qualified healthcare professionals. Common adverse reactions may include gastrointestinal disturbances, such as nausea, vomiting, and gastric irritation. It is essential for healthcare providers to consider the patient's medical history, concurrent medications, and allergies before prescribing IV Ibuprofen to mitigate the risk of any complications.

Global Intravenous (IV) Ibuprofen Market Trends:

The increasing number of surgical procedures, both elective and non-elective, is propelling the demand for effective post-operative pain management solutions, which represents one of the key factors driving the growth of the market across the globe. IV Ibuprofen, with its fast-acting pain relief capabilities, is becoming a preferred choice for managing pain in surgical settings, which is driving its market growth. The market is also driven by the growing aging population, which is leading to a rise in the prevalence of chronic pain conditions, joint-related issues, and age-related surgeries. IV Ibuprofen provides a viable solution for pain management in elderly patients who face difficulty taking oral medications, thus making it a significant driver of the market. IV Ibuprofen's pharmacokinetic advantages, such as faster absorption and higher bioavailability as compared to oral formulations, are making it an attractive option for healthcare providers. The convenience and effectiveness of the intravenous route are fostering its adoption in various medical facilities. The opioid epidemic and concerns over the potential for addiction are rising the search for non-opioid alternatives for pain management. IV Ibuprofen, being a non-opioid analgesic, is gathering attention as a safer option for pain relief, which is driving its market growth. As more clinical data support the efficacy and safety of IV Ibuprofen, healthcare institutions are increasingly adding it to their formulary. Inclusion in hospital formularies enhances accessibility and adoption of IV Ibuprofen in patient care, which is creating a positive outlook for the market across the globe. Looking forward, the market value is projected to reach US$ 12.6 Billion by 2032, expanding at a CAGR of 6.79% during 2024-2032.

Market Summary:

  • Based on the product dose, the market has been segmented into 100 Mg dose, 200 Mg dose, 400 Mg dose, and 800 Mg dose.
  • On the basis of the indication, the market has been bifurcated into pain/inflammatory and fever. Presently, pain/inflammatory holds the largest market share across the globe.
  • Based on the basis of the age group, the market has been divided into pediatrics and adults. Currently, adults dominate the market across the globe.
  • Based on the region, the market has been divided into North America (United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. Presently, North America holds the largest market share across the globe.
  • The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market. Some of the key players include Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Recordati Rare Diseases Inc., VALMOR Laboratories CA, and Xgen Pharmaceuticals Djb Inc.

Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Segment Coverage Product Dose, Indication, Age Group, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Recordati Rare Diseases Inc., VALMOR Laboratories CA and Xgen Pharmaceuticals Djb Inc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Intravenous (IV) Ibuprofen Market to Reach US$ 12.6 Billion by 2032, Driven by Rising Number of Surgical Procedures
Purchase options

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us

Phone: +1-631-791-1145


Phone: +91-120-433-0800


Phone: +44-753-714-6104


Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More